# IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Canonical URL: https://biopharmsignal.com/news/IDYA/ideaya-announces-closing-of-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares
Ticker: IDYA
Company: IDEAYA Biosciences
Source: IDEAYA Biosciences
Published: 2026-06-25 13:46 EST
Original Source URL: https://media.ideayabio.com
## Summary

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 7,222,225 shares of its common stock at a public offering price of $27.00 per share,...

## Article Body
, / PRNewswire / -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 7,222,225 shares of its common stock at a public offering price of $27.00 per share, before underwriting discounts and commissions, and pre-funded warrants to purchase 5,555,576 shares of common stock at a public offering price of $26.9999 per pre-funded warrant, before underwriting discounts and commissions. This includes the exercise in full by the underwriters of their option to purchase up to an additional 1,666,669 shares of common stock in the offering. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by IDEAYA, were approximately $345.0 million.

J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor acted as joint book-running managers for the offering. Wedbush PacGrow acted as lead manager for the offering.

The public offering was made by IDEAYA pursuant to an automatically effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission, or the SEC. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov . Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by request from: J.P. Morgan, by mail at J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmorganchase.com and postsalemanualrequests@broadridge.com ; Jefferies, by mail at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at Prospectus_Department@Jefferies.com ; TD Securities, by mail at TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com ; UBS Investment Bank, by mail at UBS Securities LLC, 11 Madison Avenue, New York, NY 10010, Attention: Equity Syndicate, or by email at ol-prospectus-request@ubs.com ; or Cantor, by mail at Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com .

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Investor and Media Contact IDEAYA Biosciences Joshua Bleharski, Ph.D. Chief Financial Officer investor@ideayabio.com

SOURCE IDEAYA Biosciences, Inc.
## Recent Company News
- 2026-07-17 13:00 EST — [IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs](https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-esmo-2026-presentations-for-darovasertib-and-ide849-3e0620d8) — Source: IDEAYA Biosciences
- 2026-06-26 10:00 EST — [IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--9011f3a6) — Source: IDEAYA Biosciences
- 2026-06-25 13:46 EST — [IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors](https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-yujiro-s-hata-elected-chairman-of-its-board-of-directors) — Source: IDEAYA Biosciences
- 2026-06-25 13:46 EST — [IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers](https://biopharmsignal.com/news/IDYA/ideaya-biosciences-announces-ide892-a-potential-best-in-class-mta-cooperative-prmt5-inhibitor-initiates-a-phase-1-2-clinical-combination-study-in-mtap-deleted-pancreatic-and-lung-cancers) — Source: IDEAYA Biosciences
- 2026-06-25 13:46 EST — [IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares](https://biopharmsignal.com/news/IDYA/ideaya-announces-closing-of-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares) — Source: IDEAYA Biosciences
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)